miR-145 is a potential biomarker for predicting clinical outcome in glioblastomas
miR-145 is a potential biomarker for predicting clinical outcome in glioblastomas
复制标题
miR-145是预测胶质母细胞瘤临床结果的潜在生物标志物
DOI：
10.1002/jcb.28079
复制
发表时间：
2019
影响因子：
4
通讯作者：
Zhu Haifeng
中科院分区：
文献类型：
--
作者：
Shi Lei;Wang Bin;Gu Xiaoyan;Zhang Shuguang;Li Xiaoliang;Zhu Haifeng
miR - 145在胶质瘤中被发现显著下调，miR - 145的过表达增加胶质瘤细胞凋亡，增强单纯疱疹病毒胸苷激酶基因治疗的化学敏感性。然而，miR - 145与胶质母细胞瘤临床预后之间的相关性从未被探讨过。本研究对86例神经外科联合放化疗后的胶质母细胞瘤患者和36例外伤性脑损伤患者进行回顾性研究。结果表明，miR - 145在胶质母细胞瘤组织中的表达明显低于正常脑组织（P< 0.05）。此外，Karnofsky绩效量表（KPS）评分较低的患者miR - 145低于KPS评分较高的患者（P< 0.05）。Cox回归分析显示miR - 145低表达与患者生存差相关（P< 0.05）。这些数据表明miR - 145低表达的胶质母细胞瘤患者总生存期较短。
miR‐145 has been found to be significantly downregulated in gliomas, and overexpression of miR‐145 increases glioma cell apoptosis and enhances chemosensitivity or herpes simplex virus thymidine kinase gene therapy. However, the correlation between miR‐145 and the clinical prognosis of glioblastomas has never been explored. In this study, a retrospective study was conducted in 86 cases of patients with glioblastoma after neurosurgery combined with chemoradiotherapy, and 36 cases with traumatic brain injury. Our results showed that miR‐145 was significantly lower in glioblastoma tissues than that in normal brain tissue (P< 0.05). Furthermore, miR‐145 was lower in patients with lower Karnofsky Performance Scale (KPS) scores than in patients with higher KPS scores (P< 0.05). Cox Regression analysis showed that low miR‐145 expression was associated with poor patient survival (P< 0.05). These data suggested that patients with glioblastoma with lower miR‐145 expression are prone to shorter overall survival.